Novo Nordisk launches Ozempic, Fiasp in U.S.

Print Friendly, PDF & Email

PLAINSBORO, N.J. — Novo Nordisk has released two new diabetes medications, Ozempic (semaglutide injection 0.5 mg and 1 mg) and Fiasp (insulin aspart injection 100 units/ml), to U.S. pharmacies.

Both medications gained Food and Drug Administration approval in 2017 and mark the latest advancements to Novo Nordisk’s diabetes portfolio, the company said Monday.

Ozempic is a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

A fast-acting mealtime insulin, Fiasp is indicated to improve glycemic control in adults with type 1 and type 2 diabetes. Novo Nordisk noted that Fiasp is the first fast-acting mealtime insulin injection without a pre-meal dosing recommendation.

“With 1.5 million new patients diagnosed with diabetes each year, we must continue to innovate and bring to market new options to meet the diverse needs of patients,” stated David Moore, senior vice president of commercial for Novo Nordisk. “There is no one-size-fits-all approach to effectively managing diabetes, and we are proud to add Ozempic and Fiasp to our market-leading portfolio to give patients new treatment options. Our robust portfolio of diabetes products addresses the concerns and needs of people with diabetes, particularly around dosing and administration.”



Comments are closed.